drugset / Trial / NCT05645276
A Study of AK129 in Patients With Advanced Malignant Tumors
NaSingle-groupOpen-labelTreatment
Summary
A Phase Ia/Ib, open label, dose escalation and dose extension trial of Anti-PD-1 and LAG-3 bispecific antibody, AK129, to evaluate the safety, tolerability and antitumor efficacy in patients with advanced malignant tumors
Timeline
- Start
- 2023-03-02
- Primary completion
- 2026-02
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AK129 | Unknown | 0.03 mg/kg | Intravenous |
| Subject | AK129 | Unknown | 0.1 mg/kg | Intravenous |
| Subject | AK129 | Unknown | 0.3 mg/kg | Intravenous |
| Subject | AK129 | Unknown | 1 mg/kg | Intravenous |
| Subject | AK129 | Unknown | 3 mg/kg | Intravenous |
| Subject | AK129 | Unknown | 10 mg/kg | Intravenous |
| Subject | AK129 | Unknown | 25 mg/kg | Intravenous |